Compound Identity
Tesamorelin at a Glance
Tesamorelin is a synthetic analog of full-length human growth hormone releasing hormone GHRH(1-44) with an N-terminal trans-3-hexenoic acid modification. The modification confers protease resistance while preserving full receptor agonist activity. Extensively characterized in peer-reviewed research on visceral adipose tissue biology.
Compound Class
Stabilized GHRH(1-44) analog
CAS Number
218949-48-5
Molecular Formula
C₂₁₄H₃₄₂N₄₂O₄₉S
Molecular Weight
5,195.8 Da
Structure
N-terminal trans-3-hexenoic acid + human GHRH(1-44)
Receptor Target
Growth hormone releasing hormone receptor (GHRHR)
Half-Life
~26-38 minutes (subcutaneous, extended vs native GHRH)
Research Background
Published Literature
Peer-reviewed research characterizes Tesamorelin's receptor pharmacology, biochemistry, and biological activity across multiple domains. Sequence Labs supplies research-grade material; all product use is subject to laboratory research protocols and applicable regulations.
Visceral Adipose Research
Tesamorelin is the most extensively studied GHRH analog for effects on visceral adipose tissue (VAT). Multiple published Phase 3 trials in HIV-associated lipodystrophy document VAT-specific reductions of 15-18% over 26 weeks.
Trans-3-Hexenoyl Modification
The N-terminal trans-3-hexenoic acid group blocks DPP-IV cleavage at the Ala-2 position, extending the base peptide half-life ~4-5 fold vs native GHRH.
IGF-1 Response
Research documents dose-dependent IGF-1 elevation with tesamorelin, plateauing at approximately 2 mg subcutaneous. The IGF-1 response is the standard biomarker for tesamorelin GH-axis pharmacology.
Lipid Profile Research
Studies report reductions in serum triglycerides and non-HDL cholesterol concurrent with VAT reduction. Insulin sensitivity effects are neutral to mildly favorable in published research.
Independent research publications on Tesamorelin are indexed in the NIH PubMed database. Consult primary literature for detailed methodology, dosing, and outcomes across research contexts.
Search PubMedSequence Labs Supply
Available Vial Sizes
All vials lyophilized under nitrogen with silver aluminum crimp cap and ivory-label spec. Manufacture and expiration dates printed. Batch-specific COA published in the COA library.
Tesamorelin
2 mg
$95 / vial
Standard research vial. Silver crimp cap. Ivory label.
Tesamorelin
5 mg
$215 / vial
Bulk research vial. Reconstitution flexibility.
Tesamorelin
10 mg
$395 / vial
Institution / lab volume.
Quality Standards
HPLC + Mass Spec
Every batch, reverse-phase HPLC purity confirmation plus MS molecular weight identity. Chromatograms published.
ISO 17025 Lab
Analytical testing performed by ISO 17025 accredited independent laboratory. Full documentation.
Cold-Chain Shipped
Insulated packaging with -20°C gel packs. 3-day standard, overnight available.
Silver Crimp Caps
Tamper-evident silver aluminum crimp caps. Lyophilized under nitrogen. Ivory-label spec.
Reconstitution Reference
Standard Procedure
Reconstitution protocol for research-grade lyophilized Tesamorelin. Adjust diluent volume to reach the working concentration required by the research protocol.
Prepare Materials
Remove vial from cold storage. Warm to room temperature ~20 minutes. Sterile insulin syringe.
Sterilize
Swab both rubber stoppers with 70% isopropyl alcohol. Air-dry 30 seconds.
Draw Diluent
For a 5 mg vial with 2 mL diluent: working concentration is 2,500 mcg/mL. Adjust volume to preferred concentration.
Add Diluent Slowly
Inject the diluent down the inside vial wall. Never spray directly onto the lyophilized cake. Do not shake.
Gentle Dissolution
Swirl gently. Tesamorelin dissolves readily in bacteriostatic water. Solution should be clear and colorless.
Label + Store
Label vial with reconstitution date and concentration. Refrigerate 2-8°C. Reconstituted stability: ~3-4 weeks refrigerated with bacteriostatic water.
Frequently Asked Questions
Tesamorelin FAQ
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone releasing hormone (GHRH). It carries an N-terminal trans-3-hexenoic acid modification that confers protease resistance while preserving GHRH receptor agonism.
How does tesamorelin differ from sermorelin?
Sermorelin is GHRH(1-29) — unmodified, half-life ~12 minutes. Tesamorelin is GHRH(1-44) with an N-terminal trans-3-hexenoyl group, half-life ~30 minutes. Tesamorelin has substantially more Phase 3 research characterizing visceral adipose tissue effects.
How does tesamorelin differ from CJC-1295 with DAC?
Both are stabilized GHRH analogs but with different mechanisms. Tesamorelin has a chemical N-terminal modification for protease resistance and a half-life of ~30 minutes. CJC-1295 with DAC uses covalent albumin binding for an ~8-day half-life. Tesamorelin preserves pulsatility better; CJC-1295 with DAC produces sustained receptor stimulation.
Is tesamorelin FDA-approved?
Yes. Tesamorelin acetate is the active ingredient in a specific FDA-approved product indicated for reduction of visceral adipose tissue in HIV-infected adults with lipodystrophy. Research-grade tesamorelin sold for laboratory use is a distinct supply channel — not for human administration — and Sequence Labs supplies research-grade only.
What testing is done on each tesamorelin batch?
HPLC purity (typical >98%), mass spectrometry identity (5,195.8 Da target), endotoxin (LAL), residual TFA and solvents, water content, appearance. Full COA published per batch.
Order Tesamorelin Research Material
Batch-tested lyophilized vials with published COA. Standard 3-day cold-chain shipping $15. Overnight $30. Same-day dispatch on orders before 2pm ET.